Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Novavax (NASDAQ:NVAX) was on track to end its seventh consecutive session in the red territory after shares of the company ...

Shares of Novavax are trading lower Friday morning. The stock appears to be caught in a downdraft affecting COVID-19 vaccine ...

Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

Novavax reports strong immune responses from H5N1 avian flu vaccine candidate, showing promise in single and two-dose ...

Novavax, Inc. (Nasdaq: NVAX) today announced preclinical data demonstrating that Novavax's H5N1 avian pandemic influenza ...

Meanwhile, Novavax also plans to use Warp Speed funds to ramp up COVID-19 vaccine manufacturing. The company has pledged to produce 100 million vaccine doses this year, and the partners could sign ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV ...

If Novavax can turn the corner on its COVID-19 vaccine production, there will be much brighter days ahead for both investors and the billions globally who desperately need a vaccine.

The biotechnology company Novavax plans to submit complete data to the US Food and Drug Administration soon for possible emergency use authorization of its coronavirus vaccine, CEO Stanley Erck ...

The latest Novavax data confirm that it’s possible to achieve the same efficacy against COVID-19 with a more familiar technology that more people may be inclined to trust.

Novavax says it will be able to deliver 100 million doses per month by the end of September and 150 million doses per month by the end of the year. The Novavax vaccine is what's known as a protein ...